Prokaryotics
Ellen has been working in pharmaceutical and academic laboratories for more than 30 years. She has extensive experience in assay development, including routine support for medicinal chemistry (Structure Activity Relationships), as well as for high-throughput screening and molecular diagnostics in the infectious disease field. During her 18 year career at Schering Plough/Merck she supported the HCV drug programs that produced Zepatier and Victrelis from target identification and validation all the way through the clinical and post-launch phases, and played a key role in a variety of antibacterial drug discovery projects, including programs targeting P. aeruginosa and Methicillin-resistant S. aureus (MRSA). Ellen has an MD degree from Shanghai Second Medical University, and Master of Science degrees in Microbiology, Immunology and Clinical Laboratory Science from Shanghai Second Medical University and Virginia Commonwealth University/Medical College of Virginia.
This person is not in any offices
Prokaryotics
Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.